Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 18, 2021. The record date for the meeting was March 29, 2021, with 117,320,127 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three primary matters:
- Director Elections: Stockholders re-elected four Class II directors (Dennis A. Ausiello, Olivier Brandicourt, Marsha H. Fanucci, and David E.I. Pyott) to serve until the 2024 annual meeting. All four candidates received majority support, though Marsha H. Fanucci and David E.I. Pyott received a higher percentage of "Against" votes compared to the other two candidates.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation. Approximately 80% of votes cast were in favor, while roughly 20% were against.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2021, with overwhelming support.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific reasons for the higher "Against" vote percentages for directors Marsha H. Fanucci and David E.I. Pyott compared to their peers.
- Review the full proxy statement to understand the context of the 20% "Against" vote on executive compensation.
- Confirm the total number of shares outstanding (117,320,127) against the sum of votes cast and broker non-votes to ensure accurate participation metrics.